Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biodefense R&D: First Anthrax Vaccine Could Enter Phase II In 2004

This article was originally published in The Pink Sheet Daily

Executive Summary

An HHS contract is supporting the development of VaxGen's recombinant anthrax vaccine. Acambis/Baxter's second-generation smallpox vaccine ACAM-2000 is in Phase II.

You may also be interested in...



Anthrax Vaccine Is HHS' First Contract Award Under Project BioShield

VaxGen receives $877.5 mil. contract to supply 75 mil. doses of its recombinant protective antigen anthrax vaccine to the national stockpile within three years. The contract is contingent upon FDA clearing the vaccine for use under emergency conditions.

Anthrax Vaccine Is HHS' First Contract Award Under Project BioShield

VaxGen receives $877.5 mil. contract to supply 75 mil. doses of its recombinant protective antigen anthrax vaccine to the national stockpile within three years. The contract is contingent upon FDA clearing the vaccine for use under emergency conditions.

Mixed Smallpox Vaccine Stockpile Could Complicate Mass Vaccination, Bavarian Nordic Says

Smallpox vaccine candidate Imvamune has not demonstrated the potential for serious adverse events associated with Wyeth's Dryvax or Acambis/Baxter's ACAM-2000, VP-R&D Paul Chaplin, PhD, says in interview with "The Blue Sheet."

Related Content

Topics

UsernamePublicRestriction

Register

PS058613

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel